{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T01:51:04Z","timestamp":1775872264427,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,16]]},"DOI":"10.7759\/cureus.103706","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:04:36Z","timestamp":1771247076000},"source":"Crossref","is-referenced-by-count":1,"title":["Myelodysplastic Syndrome Secondary to Chimeric Antigen Receptor T-cell (CAR-T) Therapy for the Treatment of Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.7759","author":[{"given":"Waqqas","family":"Tai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Dib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swathi","family":"Gopishetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Precious","family":"Idogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afoma","family":"Anyadibe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuoluwa","family":"Ayetoran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitha","family":"Balaraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishmael","family":"Jaiyesimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar SV","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al.. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011, 117:4691-5. 10.1182\/blood-2010-10-299487","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan AJ","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al.. Diagnosis and management of multiple myeloma: a review. JAMA. 2022, 327:464-77. 10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse","volume":"30","author":"Bhatt P","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R. Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023, 30:2322-47. 10.3390\/curroncol30020179","journal-title":"Curr Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1090","article-title":"Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma","volume":"18","author":"Anderson LD Jr","year":"2022","unstructured":"Anderson LD Jr. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. Future Oncol. 2022, 18:277-89. 10.2217\/fon-2021-1090","journal-title":"Future Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja JG","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al.. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021, 398:314-24. 10.1016\/S0140-6736(21)00933-8","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje N","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, et al.. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019, 380:1726-37. 10.1056\/NEJMoa1817226","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi NC","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al.. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021, 384:705-16. 10.1056\/NEJMoa2024850","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero P","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al.. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023, 388:1002-14. 10.1056\/NEJMoa2213614","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana S","year":"2024","unstructured":"Sidana S, Peres LC, Hashmi H, et al.. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment. Haematologica. 2024, 109:777-86. 10.3324\/haematol.2023.283940","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin T","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al.. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023, 41:1265-74. 10.1200\/JCO.22.00842","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-cell therapy","volume":"12","author":"Penack O","year":"2020","unstructured":"Penack O, Koenecke C. Complications after CD19+ CAR T-cell therapy. Cancers (Basel). 2020, 12:3445. 10.3390\/cancers12113445","journal-title":"Cancers (Basel)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11034","article-title":"Therapy-related leukemia and myelodysplasia: susceptibility and incidence","volume":"92","author":"Leone G","year":"2007","unstructured":"Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007, 92:1389-98. 10.3324\/haematol.11034","journal-title":"Haematologica"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling AS","year":"2022","unstructured":"Sperling AS, Guerra VA, Kennedy JA, et al.. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022, 140:1753-63. 10.1182\/blood.2021014956","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-381426","article-title":"Second malignancies after multiple myeloma: from 1960s to 2010s","volume":"119","author":"Thomas A","year":"2012","unstructured":"Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012, 119:2731-7. 10.1182\/blood-2011-12-381426","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2007.1.317","article-title":"The treatment of relapsed and refractory multiple myeloma","author":"Richardson P","year":"2007","unstructured":"Richardson P, Mitsiades C, Schlossman R, et al.. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007, 317-23. 10.1182\/asheducation-2007.1.317","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133471","article-title":"Clonal myeloid dysplasia following CAR T-cell therapy: chicken or the egg?","volume":"15","author":"Vainstein V","year":"2023","unstructured":"Vainstein V, Avni B, Grisariu S, et al.. Clonal myeloid dysplasia following CAR T-cell therapy: chicken or the egg?. Cancers (Basel). 2023, 15:3471. 10.3390\/cancers15133471","journal-title":"Cancers (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02496-0","article-title":"Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial","volume":"29","author":"Lin Y","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, et al.. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023, 29:2286-94. 10.1038\/s41591-023-02496-0","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo A","year":"2014","unstructured":"Palumbo A, Bringhen S, Kumar SK, et al.. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014, 15:333-42. 10.1016\/S1470-2045(13)70609-0","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch T","year":"2018","unstructured":"Radivoyevitch T, Dean RM, Shaw BE, et al.. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res. 2018, 74:130-6. 10.1016\/j.leukres.2018.07.016","journal-title":"Leuk Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.09.013","article-title":"Therapy-related myelodysplasia and acute myeloid leukemia","volume":"40","author":"Bhatia S","year":"2013","unstructured":"Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013, 40:666-75. 10.1053\/j.seminoncol.2013.09.013","journal-title":"Semin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/404221-myelodysplastic-syndrome-secondary-to-chimeric-antigen-receptor-t-cell-car-t-therapy-for-the-treatment-of-relapsedrefractory-multiple-myeloma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T13:04:37Z","timestamp":1771247077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/404221-myelodysplastic-syndrome-secondary-to-chimeric-antigen-receptor-t-cell-car-t-therapy-for-the-treatment-of-relapsedrefractory-multiple-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.103706","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,16]]}}}